Field dashboard · 2006–2026 + projections to 2040

Mitochondrial medicine is moving from foundations to therapies.

This strategic dashboard reconstructs two decades of field growth, then extends the latest five-year trend to 2040. Historical estimates, observed milestones, and forward projections are labeled separately so planning signals are not mistaken for audited facts.

Explore projections Read methodology

2026 snapshot

A larger field, with access still lagging activity.

Research funding

$180M

Low-confidence modeled estimate

Active programs

Pipeline reconstruction

Active trials

Interventional PMD trials

Approved drugs

Observed EU/US milestones

Research-ready patients

13,000

Low-confidence modeled estimate

Meaningfully helped

34%

Very-low-confidence proxy

Twenty-year arc

Scientific capacity expanded faster than proven patient benefit.

From the workbook's reconstructed 2006 baseline to its 2026 estimate, funding rose from $25M to $180M, active researchers from 250 to 880, therapeutic programs from 3 to 23, and research-ready patients from 500 to 13,000. The proxy for patients meaningfully helped moved from 14% to 34%.

2009–2011

Network infrastructure

NIH ARRA support helps build NAMDC registry, criteria, biostatistics, and biorepository infrastructure.

2015

First approval anchor

The European Commission authorizes Raxone for Leber hereditary optic neuropathy.

2022

New company formation

Pretzel Therapeutics launches with a $72.5M Series A focused on mitochondrial biology.

2025

Two U.S. approvals

FDA approvals for Forzinity in Barth syndrome and Kygevvi in TK2 deficiency bring the modeled cumulative total to three.

Projection view

If the current pace persists through 2040.

Gold bars are modeled projections; blue bars are the 2026 baseline. These are scenario extensions, not forecasts of clinical success.

Research funding

8.8% CAGR · Low confidence

$180M2026

$252M2030

$385M2035

$587M2040

Active therapeutic programs

7.5% CAGR · Medium confidence

232026

312030

442035

642040

Active interventional trials

7.9% CAGR · Medium confidence

192026

262030

382035

552040

Research-ready patients

12.8% CAGR · Low confidence

13,0002026

21,0312030

38,3732035

70,0142040

Eligible treatment access

8.2% CAGR · Low confidence

60.0%2026

82.2%2030

100.0%2035

100.0%2040

Patients meaningfully helped

4.5% CAGR · Very low confidence

34.0%2026

40.5%2030

50.5%2035

62.9%2040

Metric	2021	2026	Current rate	2030	2035	2040
Research funding$M · Low confidence	$118M	$180M	8.8% CAGR	$252M	$385M	$587M
Active researcherspeople · Low confidence	688	880	5.0% CAGR	1,072	1,371	1,753
PMD publicationspapers/year · Low–medium confidence	453	575	4.9% CAGR	696	883	1,121
Patent familiesfamilies/year · Low confidence	34	46	6.2% CAGR	59	79	107
Active therapeutic programsprograms · Medium confidence	16	23	7.5% CAGR	31	44	64
Active interventional trialstrials · Medium confidence	13	19	7.9% CAGR	26	38	55
New trials startedtrials/year · Medium confidence	3	5	10.8% CAGR	8	13	21
Approved drugscumulative · High confidence	1	3	0.4 approvals/year	5	7	9
New molecular diagnosespatients/year · Low confidence	6,525	8,700	5.9% CAGR	10,951	14,602	19,469
Research-ready patientspatients · Low confidence	7,125	13,000	12.8% CAGR	21,031	38,373	70,014
Eligible treatment access% · Low confidence	40.5%	60.0%	8.2% CAGR	82.2%	100.0%	100.0%
Patients meaningfully helped% · Very low confidence	27.3%	34.0%	4.5% CAGR	40.5%	50.5%	62.9%

Methodology

Simple, transparent trend extension.

For each non-cumulative metric, the projection compounds the annualized change between 2021 and 2026. Approved drugs use the recent linear pace of 0.4 additional approvals per year. Percentage metrics are capped at 100%.

Formula: 2026 value × (2026 value ÷ 2021 value)^{(years after 2026 ÷ 5)}.

Observed anchors: named network, financing, grant, and regulatory milestones linked below.

Modeled history: most annual funding, workforce, publication, patent, diagnosis, readiness, access, and benefit values are reconstructed estimates.

Projection uncertainty: rates are held constant and do not model scientific failures, policy shifts, funding cycles, market exits, or capacity limits beyond the 100% cap.

Not medical guidance: this is a field-planning scenario, not a prediction for any person, therapy, or trial.

Observed anchors and source notes